Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most dosing/administration frequency and administration route/site details generally align with the provided label excerpts; however, several cost/price and billing/assistance-related claims are not supported by the supplied prescribing information and there is no basis to confirm those statements from the provided sections.
Category Scores
Accurate Statements
Prolia is dosed once every 6 months.
2.3 Recommended Dosage: "single subcutaneous injection once every 6 months"
Prolia should be administered by a healthcare provider.
2.3 Recommended Dosage: "Prolia should be administered by a healthcare provider."
Prolia is administered as an injection per visit.
2.3 Recommended Dosage: "60 mg... as a single subcutaneous injection once every 6 months."
Prolia is administered via subcutaneous injection in the upper arm, upper thigh, or abdomen.
2.3 Recommended Dosage: "Administer Prolia via subcutaneous injection in the upper arm, the upper thigh, or the abdomen."
If a dose of Prolia is missed, administer the injection as soon as the patient is available, then schedule injections every 6 months from the date of the last injection.
2.3 Recommended Dosage: missed dose instructions.
Prolia is supplied as a clear, colorless to pale yellow solution (may contain trace proteinaceous particles) and should not be used if discolored or cloudy or contains many particles/foreign particulate matter.
2.4 Preparation and Administration: visual inspection and product appearance.
Prolia may be removed from the refrigerator and brought to room temperature up to 25°C (77°F) in the original container, which generally takes 15 to 30 minutes; do not warm in any other way.
2.4 Preparation and Administration: room temperature instructions.
Unsupported Statements
Prolia (denosumab) is a prescription drug in the United States.
The provided label excerpts do not state prescription status.
Prolia's out-of-pocket price in the United States can vary depending on insurance coverage, pharmacy pricing, and dose schedule.
No pricing/out-of-pocket/insurance/pharmacy pricing content is present in the supplied sections.
Prolia price at the pharmacy can change based on insurance plan (copay or coinsurance).
No pricing/cost-sharing information is present in the supplied sections.
Prolia price at the pharmacy can change based on whether it is bought through a retail pharmacy versus a specialty pharmacy.
No information about retail vs specialty pharmacy pricing is present in the supplied sections.
Prolia price at the pharmacy can change based on whether a manufacturer assistance program (if eligible) or a copay card is used.
No manufacturer assistance/coupon/copay card information is present in the supplied sections.
Prolia price at the pharmacy can change based on the timing and location of the fill due to pharmacy network and negotiated rates.
No information about pharmacy network/negotiated rates/timing-location effects is present in the supplied sections.
Because Prolia is given once every 6 months, effective annual treatment involves roughly two doses per year.
While implied by the dosing interval, the provided label does not state annual dose count.
A method to estimate total annual cost is to find the per-dose cost and multiply by 2, since Prolia is typically given every 6 months.
No cost-estimation method or annual cost calculation guidance is present in the supplied label excerpts.
Administration charges may apply if the clinic bills separately for the Prolia injection.
No billing/administration charge guidance is present in the supplied label excerpts.
Contradictions
Low
AI Statement
Administration charges may apply if the clinic bills separately for the Prolia injection.
Label Reference
2 Dosage and Administration / 2.4 Preparation and Administration excerpts provided; no statement about billing charges.
Important Omissions
Calcium and vitamin D supplementation: all patients should receive calcium 1000 mg daily and at least 400 IU vitamin D daily.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The dosing frequency/route statements are largely consistent with the provided label excerpt, but the response does not include the label-required calcium/vitamin D supplementation instruction, which is material to safe administration per the provided information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple cost/insurance/billing claims are unsupported by the supplied prescribing information; additionally, required calcium/vitamin D supplementation guidance is omitted.
Suggested Improvement
Restrict statements to what is present in the label excerpts (e.g., dosing interval, subcutaneous administration sites, missed dose guidance, and administration/handling instructions) and include label-required calcium/vitamin D supplementation; remove or qualify pricing/insurance/billing content as not described in the provided label.